Literature DB >> 14870978

TH1 and TH2 lymphocyte development and regulation of TH cell-mediated immune responses of the skin.

Tilo Biedermann1, Martin Röcken, José M Carballido.   

Abstract

Since the first description of the subpopulations of TH1 and TH2 cells, insights into the development and control of these cells as two polarized and physiologically balanced subsets have been generated. In particular, implications of the TH1-TH2 concept for TH cell-mediated skin disorders have been discovered. This article will review the basic factors that control the development of TH1 and TH2 cells, such as the cytokines IL-12 and IL-4 and transcription factors, the possible role of costimulatory molecules, and specialized dendritic cell populations. These regulatory mechanisms will be discussed in the context of polarized TH1 or TH2 skin disorders such as psoriasis and atopic dermatitis. Also presented are the principles that govern how chemokines and chemokine receptors recruit TH1 and TH2 cells to inflammatory sites and how they amplify these polarized TH cell responses. All of these concepts, including a novel role for IL-4-inducing TH1 responses, can contribute to the design of better therapeutic strategies to modulate TH cell-mediated immune responses.

Entities:  

Mesh:

Year:  2004        PMID: 14870978     DOI: 10.1111/j.1087-0024.2004.00829.x

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  26 in total

Review 1.  Cutaneous perspectives on adaptive immunity.

Authors:  Michael Girardi
Journal:  Clin Rev Allergy Immunol       Date:  2007-10       Impact factor: 8.667

Review 2.  [Outside-in. Probiotic topical agents].

Authors:  T Volz; T Biedermann
Journal:  Hautarzt       Date:  2009-10       Impact factor: 0.751

Review 3.  Cytokine-based therapy in psoriasis.

Authors:  Anupam Mitra; Robyn S Fallen; Hermenio Cavalcante Lima
Journal:  Clin Rev Allergy Immunol       Date:  2013-04       Impact factor: 8.667

4.  Atopic dermatitis.

Authors:  Thomas Bieber
Journal:  Ann Dermatol       Date:  2010-05-17       Impact factor: 1.444

Review 5.  The genetics of atopic dermatitis: recent findings and future options.

Authors:  Sabine Hoffjan; Jörg T Epplen
Journal:  J Mol Med (Berl)       Date:  2005-05-18       Impact factor: 4.599

6.  Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis.

Authors:  Hermenio Cavalcante Lima; Alexandra Boer Kimball
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

7.  Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets.

Authors:  Tali Czarnowicki; Hitokazu Esaki; Juana Gonzalez; Dana Malajian; Avner Shemer; Shinji Noda; Sreya Talasila; Adam Berry; Jayla Gray; Lauren Becker; Yeriel Estrada; Hui Xu; Xiuzhong Zheng; Mayte Suárez-Fariñas; James G Krueger; Amy S Paller; Emma Guttman-Yassky
Journal:  J Allergy Clin Immunol       Date:  2015-08-01       Impact factor: 10.793

8.  Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.

Authors:  Xuhua Duan; Manzhou Wang; Xinwei Han; Jianzhuang Ren; Guohao Huang; Shuguang Ju; Qinghui Zhang
Journal:  Cell Cycle       Date:  2020-12-07       Impact factor: 4.534

9.  Prostanoid receptor 2 signaling protects T helper 2 cells from BALB/c mice against activation-induced cell death.

Authors:  Vandana Kaul; Luc Van Kaer; Gobardhan Das; Jyoti Das
Journal:  J Biol Chem       Date:  2012-05-31       Impact factor: 5.157

10.  Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum.

Authors:  Lianghua Bin; Kathleen C Barnes; Li Gao; Nicholas M Rafaels; Lili Huang; Joseph Potee; Ingo Ruczinski; Terri H Beaty; Amy S Paller; Lynda C Schneider; Rich Gallo; Jon M Hanifin; Lisa A Beck; Raif S Geha; Rasika A Mathias; Donald Y M Leung
Journal:  J Allergy Clin Immunol       Date:  2015-09-03       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.